What hip OA staging actually measures

Seeing 'Grade 3' or 'moderate OA' on a radiology report can feel alarming — or confusing — without context. The number refers to the Kellgren-Lawrence (KL) grading system, first described in 1957 and still the standard radiographic tool for classifying hip osteoarthritis. (Other systems, such as the Tönnis and Croft scales, exist in specific clinical settings, but KL is what most patients will encounter on their report and in outpatient consultations.) The scale runs from Grade 0, where the joint looks normal, to Grade 4, which shows near-total loss of the joint space. Clinicians often translate these five grades into four descriptive stages — Minor, Mild, Moderate, and Severe — each defined by what is visible on a plain X-ray: the size and number of osteophytes (bony spurs), the degree of joint space narrowing, the presence of subchondral sclerosis (hardening of the bone beneath the cartilage), and any deformity of the femoral head or socket.

Radiographic grade, however, is only one part of the picture. Some patients with KL Grade 4 changes — technically bone-on-bone disease — live with manageable discomfort, while others with KL Grade 2 find their daily life significantly curtailed. NHS Inform states this explicitly: imaging severity and symptom severity do not reliably track together. What matters clinically is how pain and functional loss affect daily life, not the number on the report. Treatment decisions follow from that reality, not from the grade alone.

Stage 1 and 2: early changes, subtle symptoms

For many people, Stage 1 (KL Grade 1) passes entirely unnoticed. The changes visible on X-ray at this point — subtle osteophytes and a possible hint of joint space narrowing — rarely produce symptoms significant enough to prompt a GP visit. Patients often discover they have early arthritis incidentally, when imaging is done for another reason.

By Stage 2 (KL Grade 2), the picture becomes more recognisable. Osteophytes are now definitively present, and there is minimal but measurable joint space narrowing. The symptoms that emerge at this level tend to be intermittent rather than constant: a nagging groin stiffness when getting out of a chair, discomfort on waking that eases once walking, or aching in the front of the hip after a longer walk. Crucially, hip OA pain does not always announce itself in the hip. It is commonly felt in the groin first, but may also appear in the outer hip, the buttock, or down the front of the thigh — and can refer as far as the knee, leading some patients to investigate their knee long before identifying the hip as the source.

Conservative management is well-matched to these early stages. Low-impact activity such as walking or swimming helps maintain joint mobility, while targeted physiotherapy can support the muscles around the hip — particularly the gluteus medius and minimus — that tend to weaken as the joint becomes stiffer. Weight management reduces load through the hip with each step, and over-the-counter analgesics such as paracetamol or ibuprofen can manage flare-ups. Early-stage OA does not follow a fixed timetable: for many patients, appropriate exercise and lifestyle adjustment can slow deterioration meaningfully, and Stage 2 disease managed well does not automatically lead to surgical assessment.

Stage 3: when pain starts to shape daily life

The shift from Stage 2 to Stage 3 (KL Grade 3) is often the point at which hip OA stops being an occasional inconvenience and becomes a steady presence. Radiographically, the joint now shows moderate-to-marked joint space narrowing, subchondral sclerosis, and sometimes small bone cysts forming beneath the joint surface. But for most patients, the clinical change is felt well before any repeat X-ray is taken: pain that was previously triggered by longer walks or mornings begins to accompany far more ordinary activities — climbing stairs, kneeling, putting on shoes, or rising from a low chair.

Crepitus — the grinding or clicking sensation within the joint — becomes more consistently noticeable at this stage. It reflects cartilage loss rather than anything dramatically new happening, but patients often find it unsettling when it first appears. It is worth knowing that crepitus alone is not a reliable guide to urgency; what matters more is whether pain is now limiting function that was previously unrestricted.

Sleep disruption is a particularly important signal at Stage 3. Pain that wakes a person at night, or prevents them finding a comfortable position, indicates that the hip is causing distress even without loading — a clinically meaningful escalation that warrants structured management review rather than continued waiting.

Physiotherapy at this stage shifts emphasis toward strengthening the hip abductor muscles (gluteus medius and minimus), which commonly weaken as gait is affected; stride length tends to shorten before most patients consciously notice their walking has changed. Intra-articular injections — corticosteroid or hyaluronic acid — may provide a useful period of symptom relief for patients managing Stage 3 disease, buying time and improving function while longer-term decisions are considered.

Stage 3 does not mean surgery is imminent or inevitable. Many patients remain at this stage for years with appropriate, active management. What it does mean is that specialist review — to map out all available options clearly — becomes a sensible, proactive step rather than something to put off until the situation becomes urgent.

Stage 4: bone-on-bone and what it means in practice

'Bone-on-bone' is the phrase that tends to land hardest when patients read an X-ray report. At KL Grade 4 (Stage 4, Severe), it is structurally accurate: cartilage has been lost to the point where the femoral head and socket are in direct contact, joint space is grossly reduced or obliterated, and large osteophytes with visible bony deformity appear on plain X-ray.

The symptom picture at this stage typically reflects that structural reality. Pain is no longer reliably tied to activity — it is often present at rest and disturbs sleep. Analgesics and activity pacing, which can manage earlier stages meaningfully, tend to offer only partial or inconsistent relief. Gait is commonly affected: stride length shortens, the hip abductor muscles (gluteus medius and minimus) fatigue more readily, and some patients develop an antalgic pattern — leaning slightly over the affected side to offload it.

As established in the staging overview, imaging grade and symptom burden do not always track together, so a Grade 4 report is not automatically a surgical mandate.

The signals that tend to move the conversation toward formal surgical assessment are functional, not radiographic: persistent sleep disruption from pain, difficulty managing stairs, inability to rise from a low chair without assistance, or loss of the ability to dress independently. When conservative measures — physiotherapy, injections, analgesia — have been systematically tried and the improvements have become marginal, hip replacement enters the discussion as a well-founded option rather than a last resort.

Hip replacement is among the most evidence-supported operations in modern orthopaedic practice, with approximately 58% of implants lasting 25 years and modern technique supporting considerably longer. What the decision actually involves — and how it is reached — is covered next.

How the replacement decision is actually made

Reaching the conversation about hip replacement does not mean the decision has already been made. The NHS framework for hip OA — set out in NHS England's patient decision guide — is explicitly staged: conservative options should be tried and, where possible, exhausted before surgery is recommended. What moves the discussion forward is not a number on a radiograph but the accumulation of functional evidence covered in the previous section: when non-operative measures have been systematically tried and meaningful improvement has become consistently elusive, the calculus begins to shift.

At that point, a central part of the assessment becomes timing. Implant longevity is a genuine factor in the conversation. Current evidence suggests around 58% of total hip replacements last 25 years, and modern muscle-sparing approaches may support longer durability in appropriate patients — though this depends on individual anatomy, activity level, and implant choice rather than technique alone. Age and expected functional demand therefore matter: a patient in their mid-fifties with significant bilateral disease presents different considerations from someone in their mid-seventies with one affected joint. Neither answer is automatic, and a rushed decision in either direction carries real costs.

This is where before-replacement assessment earns its clinical value. Rather than a referral that assumes surgery as the endpoint, the aim is a structured review — of what has actually been tried, what the imaging shows in relation to function, and what each option realistically offers going forward. Professor Paul Lee's approach at the London Cartilage Clinic is built around that model: assessing patients across the full range of options, conservative and surgical, before recommending any course of action. That includes identifying when the right answer is to wait. Knowing when surgery is appropriate and when it is not is what separates a specialist hip assessment from a pre-operative appointment.

Muscle-sparing surgery and what it means for recovery

Understanding what surgery actually involves helps patients ask better questions before committing to it.

In a standard total hip replacement using a posterior approach, the surgeon gains access to the joint by cutting through or detaching some of the muscles and tendons at the back of the hip — structures that must then be repaired and allowed to heal. Muscle-sparing variants aim to reduce this soft-tissue disruption. Rather than dividing the posterior tendons, they work between or around them, preserving the structures that contribute to joint stability after the implant is placed.

The SPAIRE technique — developed by Professor Paul Lee during his fellowship at the Exeter Hip Unit — takes this principle a step further by specifically preserving the piriformis and obturator internus tendons while repairing the obturator externus. The clinical rationale is that keeping these structures intact may support early joint stability, reduce the theoretical risk of dislocation, and allow mobilisation to begin sooner in patients for whom the approach is suitable. Professor Lee combines the technique with a structured biological rapid recovery programme that integrates implant selection, mobilisation, and post-operative planning as a coordinated pathway rather than separate decisions.

Within that pathway, selected patients may be discharged the same day or the following day, compared with the three-to-five day stay associated with more conventional approaches. Whether that is appropriate depends on individual anatomy, fitness, and recovery — it is not a universal feature of muscle-sparing surgery.

Muscle-sparing techniques are not available everywhere, and suitability is always assessed individually. What they represent, where they are offered, is a shift in how surgical access and recovery are designed — prioritising the patient's biology from the outset. Understanding that such options exist, and what the evidence behind them looks like, is part of what makes a pre-operative specialist assessment worthwhile.